Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01238575 · ClinicalTrials.gov registry record · Phase 4
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
A Phase 4 study of Pervasive Development Disorders, sponsored by Yale University.
- Completed
- Registry status
- Phase 4
- Development phase
- 62
- Enrollment target
- 5
- Study locations
NCT01238575 is a Phase 4 study of Pervasive Development Disorders that has completed, run by Yale University. The registered enrollment target is 62 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT01238575, a Phase 4 study of Pervasive Development Disorders, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 62 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine whether guanfacine (trade name Intuniv) by itself or in combination with methylphenidate (also known as Ritalin) is helpful for treating hyperactivity in children and adolescents with a Pervasive Developmental Disorders (PDDs).
Conditions Studied
Interventions
- OTHER placebo
- DRUG extended-release guanfacine
Study Locations (5)
California
- University of California, Los Angeles - Los Angeles
Connecticut
- Yale University - New Haven
Georgia
- Emory University - Atlanta
Massachusetts
- Massachusetts General Hospital - Lexington
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01238575
The ClinicalTrials.gov registry entry for NCT01238575 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pervasive Development Disorders appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01238575 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Connecticut, Georgia.
Frequently Asked Questions
What is clinical trial NCT01238575 about?
NCT01238575 is a clinical study titled "Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder". The purpose of this study is to determine whether guanfacine (trade name Intuniv) by itself or in combination with methylphenidate (also known as Ritalin) is helpful for treating hyperactivity in children and adolescents with a Pervasive Developmental Disorders (PDDs).
What is the current status of trial NCT01238575?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 62 participants. The study started on 2011-12. Estimated completion is 2014-03.
What conditions does trial NCT01238575 study?
This clinical trial studies the following conditions: Pervasive Development Disorders.
What interventions are being tested in trial NCT01238575?
The interventions under investigation include: placebo (OTHER), extended-release guanfacine (DRUG).
Who is sponsoring clinical trial NCT01238575?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01238575 being conducted?
This trial has 5 study locations across California, Connecticut, Georgia, Massachusetts, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.